Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
University of Washington
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
University Hospital Schleswig-Holstein
University Hospital Muenster
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
St. Jude Children's Research Hospital
University of Washington
St. Jude Children's Research Hospital
University of California, San Diego
First Affiliated Hospital Xi'an Jiaotong University
Gruppo Italiano Malattie EMatologiche dell'Adulto
Universität des Saarlandes
Universität des Saarlandes
Universität des Saarlandes
St. Jude Children's Research Hospital
PETHEMA Foundation
PETHEMA Foundation
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
University of Utah
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Massachusetts General Hospital
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
PETHEMA Foundation
Ruijin Hospital
Centre Henri Becquerel
University of California, San Francisco
University Hospital Schleswig-Holstein
Dana-Farber Cancer Institute
Northwestern University
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Bologna